What is he best known for?
The fields of study Bo Ahrén is best known for:
- Diabetes mellitus
- Pancreas
- Type 2 diabetes
Bo Ahrén combines Internal medicine and Pathology in his studies.
He conducts interdisciplinary study in the fields of Pathology and Internal medicine through his research.
His study brings together the fields of Secretion and Endocrinology.
Bo Ahrén integrates Insulin with Insulin resistance in his research.
Insulin resistance is closely attributed to Pancreatic hormone in his research.
His Pancreatic hormone study frequently draws connections to adjacent fields such as Insulin.
His Diabetes mellitus study frequently intersects with other fields, such as Islet.
Much of his study explores Islet relationship to Diabetes mellitus.
His work often combines Type 2 diabetes and Vildagliptin studies.
His most cited work include:
- Interleukin-6-deficient mice develop mature-onset obesity (1087 citations)
- The High-Fat Diet–Fed Mouse (870 citations)
- Antidiabetogenic Effect of Glucagon-like Peptide-1 (7–36)amide in Normal Subjects and Patients with Diabetes Mellitus (804 citations)
What are the main themes of his work throughout his whole career to date
His Stimulation research extends to Internal medicine, which is thematically connected.
His Endocrinology study frequently draws connections to other fields, such as Secretion.
Many of his studies involve connections with topics such as Islet and Insulin.
Many of his studies on Islet apply to Diabetes mellitus as well.
While working on this project, Bo Ahrén studies both Diabetes mellitus and Incretin.
Bo Ahrén combines Incretin and Type 2 diabetes in his research.
Bo Ahrén combines Type 2 diabetes and Insulin in his research.
He regularly ties together related areas like Neuropeptide in his Receptor studies.
His Neuropeptide study frequently draws connections between adjacent fields such as Receptor.
Bo Ahrén most often published in these fields:
- Internal medicine (97.20%)
- Endocrinology (91.80%)
- Insulin (72.60%)
What were the highlights of his more recent work (between 2013-2021)?
- Endocrinology (100.00%)
- Internal medicine (100.00%)
- Type 2 diabetes (90.00%)
In recent works Bo Ahrén was focusing on the following fields of study:
His Insulin resistance research is covered under the topics of Glucose homeostasis and Pancreatic hormone.
His research on Pancreatic hormone often connects related topics like Insulin resistance.
Bo Ahrén regularly ties together related areas like Ingestion in his Endocrinology studies.
His Ingestion study frequently draws connections between related disciplines such as Internal medicine.
His work on Internal medicine is being expanded to include thematically relevant topics such as Glucagon receptor.
In his works, Bo Ahrén undertakes multidisciplinary study on Type 2 diabetes and Postprandial.
Bo Ahrén performs multidisciplinary study on Postprandial and Type 2 diabetes in his works.
His research links Glucose homeostasis with Diabetes mellitus.
Insulin is closely attributed to Glucagon receptor in his work.
Between 2013 and 2021, his most popular works were:
- HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin (186 citations)
- Surrogate measures of insulin sensitivity vs the hyperinsulinaemic–euglycaemic clamp: a meta-analysis (109 citations)
- Pleiotropic Mechanisms for the Glucose-Lowering Action of DPP-4 Inhibitors (94 citations)
In his most recent research, the most cited works focused on:
- Diabetes mellitus
- Type 2 diabetes
- Insulin resistance
His study on Endocrinology is mostly dedicated to connecting different topics, such as Sitagliptin.
His research on Internal medicine often connects related topics like Glimepiride.
Bo Ahrén conducted interdisciplinary study in his works that combined Glimepiride and Metformin.
In his study, he carries out multidisciplinary Metformin and Sitagliptin research.
Bo Ahrén combines Type 2 diabetes and Liraglutide in his research.
Bo Ahrén merges many fields, such as Diabetes mellitus and Exenatide, in his writings.
His work on Postprandial expands to the thematically related Insulin.
He integrates many fields, such as Postprandial and Type 2 diabetes, in his works.
Bo Ahrén combines Glucagon and Glucagon receptor in his studies.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
